$4.37
+1.15
(+35.71%)▲
27.69%
Downside
Day's Volatility :34.3%
Upside
9.15%
39.02%
Downside
52 Weeks Volatility :84.43%
Upside
74.46%
Period | Theriva Biologics Inc | Index (Russel 2000) |
---|---|---|
3 Months | -33.71% | 0.0% |
6 Months | -62.0% | 0.0% |
1 Year | -65.59% | 0.0% |
3 Years | -83.04% | -22.3% |
Market Capitalization | 3.2M |
Book Value | $28.92 |
Earnings Per Share (EPS) | -31.25 |
Wall Street Target Price | 100.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -24.98% |
Return On Equity TTM | -59.06% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -21.4M |
Diluted Eps TTM | -31.25 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -26.5 |
EPS Estimate Next Year | -18.5 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | -6.25 |
What analysts predicted
Upside of 2188.33%
Sell
Neutral
Buy
Theriva Biologics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Theriva Biologics Inc | -15.84% | -62.0% | -65.59% | -83.04% | -83.04% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Theriva Biologics Inc | NA | NA | NA | -26.5 | -0.59 | -0.25 | NA | 28.92 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Theriva Biologics Inc | Buy | $3.2M | -83.04% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Theriva Biologics Inc
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 102.7%
synthetic biologics, inc. (nyse mkt: syn) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. the company's lead candidates poised for phase 3 development are: (1) syn-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (ibs-c), and (2) syn-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (iv) beta-lactam antibiotics for the prevention of c. difficile infection (cdi), antibiotic-associated diarrhea (aad) and the emergence of antimicrobial-resistance (amr). the company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (pku).
Organization | Theriva Biologics Inc |
Employees | 22 |
CEO | Mr. Steven A. Shallcross CPA |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$4.37
+35.71%
Keyarch Acquisition Corp
$4.37
+35.71%
Connexa Sports Technologies Inc
$4.37
+35.71%
Us Value Etf
$4.37
+35.71%
First Wave Biopharma Inc
$4.37
+35.71%
Global X Msci Next Emerging
$4.37
+35.71%
Fat Projects Acquisition Corp
$4.37
+35.71%
Capital Link Global Fintech
$4.37
+35.71%
Applied Uv Inc
$4.37
+35.71%